Microdermics Inc., a hollow microneedle technology company, has raised undisclosed amount of seed funding from e@UBC Seed Fund.
Vancouver based Microdermics is developing a microneedle that is only one-tenth as wide as a syringe needle and practically painless. Using microfluidics and optics, the new device is designed to monitor levels of the antibiotic vancomycin without drawing blood. Microdermics also designs, tests, and produces customized microneedles for the delivery of vaccines and therapeutics that will eliminate the reliance on traditional hypodermic needles.
Microdermics currently is part of the first cohort at HATCH, UBC’s on-campus incubator for tech ventures advancing to the stage of launching their businesses.
Capitalized by contributions of UBC alumni and others, e@UBC Seed Fund invests risk capital in new and innovative startups founded by UBC students, recent alumni, faculty and staff. The Fund has invested in 13 companies to date.
photo credit: Microdermics